First human tests for new obesity drug begin

NCT ID NCT06637020

Summary

This early-stage study tested the safety and how the body processes a new injectable drug called HDM1005 in people who are overweight or obese. Forty participants received either the drug or a placebo (inactive shot) at different dose levels to see how well it was tolerated. The main goal was to check for side effects and determine safe dosage ranges for future research on weight control.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230000, China

Conditions

Explore the condition pages connected to this study.